Alimera Sciences - ALIM Stock Forecast, Price & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alimera Sciences in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ALIM shares.
View ALIM analyst ratings or view top-rated stocks.

2 Wall Street analysts have issued 12 month target prices for Alimera Sciences' stock. Their ALIM share price forecasts range from $4.50 to $9.00. On average, they expect the company's stock price to reach $6.75 in the next year. This suggests a possible upside of 159.6% from the stock's current price.
View analysts price targets for ALIM or view top-rated stocks among Wall Street analysts.

Alimera Sciences' stock was trading at $2.71 at the beginning of the year. Since then, ALIM stock has decreased by 4.1% and is now trading at $2.60.
View the best growth stocks for 2023 here.

Alimera Sciences saw a drop in short interest during the month of January. As of January 15th, there was short interest totaling 21,500 shares, a drop of 9.7% from the December 31st total of 23,800 shares. Based on an average trading volume of 14,300 shares, the days-to-cover ratio is currently 1.5 days. Currently, 0.4% of the company's stock are sold short.
View Alimera Sciences' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our ALIM earnings forecast.

Alimera Sciences, Inc. (NASDAQ:ALIM) released its quarterly earnings results on Monday, November, 14th. The biopharmaceutical company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.37) by $0.38. The biopharmaceutical company earned $13.60 million during the quarter, compared to the consensus estimate of $15.60 million.

Alimera Sciences's stock reverse split on Friday, November 15th 2019. The 1-15 reverse split was announced on Thursday, November 7th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, November 14th 2019. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

2 employees have rated Alimera Sciences Chief Executive Officer Rick Eiswirth on Glassdoor.com. Rick Eiswirth has an approval rating of 100% among the company's employees. This puts Rick Eiswirth in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Alimera Sciences investors own include EyePoint Pharmaceuticals (EYPT), OPKO Health (OPK), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Advanced Micro Devices (AMD), Amarin (AMRN), AngloGold Ashanti (AU), SSR Mining (SSRM), ADMA Biologics (ADMA) and Cellectar Biosciences (CLRB).

Alimera Sciences trades on the NASDAQ under the ticker symbol "ALIM."

Shares of ALIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ALIM stock can currently be purchased for approximately $2.60.

Alimera Sciences (NASDAQ:ALIM) has a market capitalization of $18.20 million and generates $59.03 million in revenue each year. The biopharmaceutical company earns $-4,370,000.00 in net income (profit) each year or ($2.64) on an earnings per share basis.

The company employs 145 workers across the globe.

Alimera Sciences' mailing address is 6120 WINDWARD PARKWAY STE 290, ALPHARETTA GA, 30005. The official website for the company is www.alimerasciences.com. The biopharmaceutical company can be reached via phone at (678) 990-5740, via email at scottg@coreir.com, or via fax at 678-990-5744.